Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma

BMC Veterinary Research

Jessika-MV Cavalleri¹  Marcus Doherr²  Mareu Hellige¹  Detlef Oswald⁴  Hans-Joachim Schuberth³  Anne Endmann⁴  Christiane Juhls⁴  Karsten Feige¹  Kathrin Mählmann¹ 

[1]Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany

[2]Institute for Veterinary Epidemiology and Biostatistics, Free University of Berlin, Berlin, Germany

[3]Immunology Unit, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany

[4]Mologen AG, Berlin, Germany

关键词: DNA vaccine;    Tyrosinase;    Glycoprotein 100;    Interleukin;    Melanoma;    Horse;   

Others  :  1206133
DOI  :  10.1186/s12917-015-0414-9

 received in 2014-10-13, accepted in 2015-04-15,  发布年份 2015

【 摘 要 】

Background

Equine melanoma has a high incidence in grey horses. Xenogenic DNA vaccination may represent a promising therapeutic approach against equine melanoma as it successfully induced an immunological response in other species suffering from melanoma and in healthy horses. In a clinical study, twenty-seven, grey, melanoma-bearing, horses were assigned to three groups (n = 9) and vaccinated on days 1, 22, and 78 with DNA vectors encoding for equine (eq) IL-12 and IL-18 alone or in combination with either human glycoprotein (hgp) 100 or human tyrosinase (htyr). Horses were vaccinated intramuscularly, and one selected melanoma was locally treated by intradermal peritumoral injection. Prior to each injection and on day 120, the sizes of up to nine melanoma lesions per horse were measured by caliper and ultrasound. Specific serum antibodies against hgp100 and htyr were measured using cell based flow-cytometric assays. An Analysis of Variance (ANOVA) for repeated measurements was performed to identify statistically significant influences on the relative tumor volume. For post-hoc testing a Tukey-Kramer Multiple-Comparison Test was performed to compare the relative volumes on the different examination days. An ANOVA for repeated measurements was performed to analyse changes in body temperature over time. A one-way ANOVA was used to evaluate differences in body temperature between the groups. A p–value < 0.05 was considered significant for all statistical tests applied.

Results

In all groups, the relative tumor volume decreased significantly to 79.1 ± 26.91% by day 120 (p < 0.0001, Tukey-Kramer Multiple-Comparison Test). Affiliation to treatment group, local treatment and examination modality had no significant influence on the results (ANOVA for repeated measurements). Neither a cellular nor a humoral immune response directed against htyr or hgp100 was detected. Horses had an increased body temperature on the day after vaccination.

Conclusions

This is the first clinical report on a systemic effect against equine melanoma following treatment with DNA vectors encoding eqIL12 and eqIL18 and formulated with a transfection reagent. Addition of DNA vectors encoding hgp100 respectively htyr did not potentiate this effect.

【 授权许可】

   
2015 Mählmann et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Seltenhammer MH, Simhofer H, Scherzer S, Zechner R, Curik I, Solkner J et al.. Equine melanoma in a population of 296 grey Lipizzaner horses. Equine Vet J. 2003; 35:153-7.
• [2]Pilsworth RC, Knottenbelt D. Melanoma. Equine vet Educ. 2006; 18:228-30.
• [3]Montes LF, Vaughan JT, Ramer G. Equine melanoma. J Cutan Pathol. 1997; 6:234-5.
• [4]Theon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995–2004). J Am Vet Med Assoc. 2007; 230:1506-13.
• [5]Laus F, Cerquetella M, Paggi E, Ippedico G, Argentieri M, Castellano G et al.. Evaluation of Cimetidine as a therapy for dermal melanomatosis in grey horse. Isr J Vet Med. 2010; 65:48-52.
• [6]Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB et al.. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000; 128:273-80.
• [7]Schreurs MW, de Boer AJ, Figdor CG, Adema GJ. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. 1998; 58:2509-14.
• [8]Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS et al.. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Canc Immunol. 2009; 9:5.
• [9]Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH et al.. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol. 1995; 7:1135-45.
• [10]Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C et al.. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine. 2006; 24:4582-5.
• [11]Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, Perales MA et al.. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res. 2005; 11:8114-21.
• [12]Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C et al.. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Canc Immunol. 2006; 6:8.
• [13]Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J et al.. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther. 2007; 2044–2050:15.
• [14]Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME et al.. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol. 2003; 170:5188-94.
• [15]Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K et al.. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998; 188:277-86.
• [16]Zhou WZ, Kaneda Y, Huang S, Morishita R, Hoon D. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Therapy. 1999; 6:1768-1773.
• [17]Lembcke LM, Kania SA, Blackford JT, Trent DJ, Grosenbaugh DA, Fraser DG et al.. Development of immunologic assays to measure response in horses vaccinated with xenogeneic plasmid DNA encoding human tyrosinase. J Equine Vet Sci. 2012; 32:607-15.
• [18]Alton EW, Geddes DM, Gill DR, Higgins CF, Hyde SC, Innes JA et al.. Towards gene therapy for cystic fibrosis: a clinical progress report. Gene Ther. 1998; 5:291-2.
• [19]Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT et al.. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol. 1998; 160:1320-9.
• [20]Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE et al.. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Investig. 1998; 101:1441-52.
• [21]Gherardi MM, Ramirez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol. 2000; 74:6278-86.
• [22]Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol. 1997; 158:4591-601.
• [23]Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol. 1999; 73:501-9.
• [24]Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ et al.. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther. 2000; 7:83-90.
• [25]Kishida T, Asada H, Satoh E, Tanaka S, Shinya M, Hirai H et al.. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 2001; 8:1234-40.
• [26]Tamura T, Nishi T, Goto T, Takeshima H, Ushio Y, Sakata T. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res. 2003; 23:1173-9.
• [27]Heinzerling L, Dummer R, Pavlovic J, Schultz J, Burg G, Moelling K. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol. 2002; 11:232-40.
• [28]Müller J, Feige K, Wunderlin P, Hodl A, Meli ML, Seltenhammer M et al.. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother. 2011; 34:58-64.
• [29]Schirmbeck R, Konig-Merediz SA, Riedl P, Kwissa M, Sack F, Schroff M et al.. Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med. 2001; 79:343-50.
• [30]Endmann A, Baden M, Weisermann E, Kapp K, Schroff M, Kleuss C et al.. Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine. 2010; 28:3642-9.
• [31]Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G et al.. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med. 2001; 78:692-702.
• [32]Endmann A, Klünder K, Kapp K, Riede O, Oswald D, Talman EG et al.. Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine. PLoS One. 2014; 9(7):e101715.
• [33]Dow SW, Elmslie RE, Fradkin LG, Liggitt DH, Heath TD, Willson AP et al.. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther. 1999; 10:2961-72.
• [34]Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol. 1999; 163:1552-61.
• [35]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al.. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst. 2000; 92:205-16.
• [36]Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C et al.. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15:7412-20.
• [37]Phillips JC, Blackford JT, Lembcke LM, Grosenbaugh DA, Leard T. Evaluation of needle-free injection devices for intramuscular vaccination in horses. J Equine Vet Sci. 2011; 31:738-43.
• [38]Phillips JC, Lembcke LM, Noltenius CE, Newman SJ, Blackford JT, Grosenbaugh DA et al.. Evaluation of tyrosinase expression in canine and equine melanocytic tumors. Am J Vet Res. 2012; 73:272-8.
• [39]Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H et al.. Comparative histopathology of grey-horse-melanoma and human malignant melanoma. Pigment Cell Res. 2004; 17:674-81.
• [40]Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R et al.. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994; 12:1036-44.
• [41]Romero P, Cerottini JC, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today. 1998; 4:305-12.
• [42]Heinzerling L, Basch V, Maloy K, Johansen P, Senti G, Wuthrich B et al.. Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine. 2006; 24:1389-94.